Cuthbertson, DJ and Weickert, MO and Lythgoe, D and Sprung, VS and Dobson, R and Shoajee-Moradie, F and Umpleby, M and Pfeiffer, AFH and Thomas, EL and Bell, JD and Jones, H and Kemp, GJ (2014) External validation of the fatty liver index and lipid accumulation product indices, using H-1-magnetic resonance spectroscopy, to identify hepatic steatosis in healthy controls and obese, insulin-resistant individuals. EUROPEAN JOURNAL OF ENDOCRINOLOGY, 171 (5). pp. 561-569. ISSN 0804-4643
FLI Manuscript 2010.02.14 EJE.pdf
Background and Aims. Simple clinical algorithms including the Fatty Liver Index (FLI) and Lipid Accumulation Product (LAP) have been developed as a surrogate marker for Non-Alcoholic Fatty Liver Disease (NAFLD). These algorithms have been constructed using ultrasonography, a semi-quantitative method. This study aimed to validate FLI and LAP as measures of hepatic steatosis, as measured quantitatively by proton magnetic resonance spectroscopy (1H-MRS).
Methods. Data were collected from 168 patients with NAFLD and 168 controls who had undergone clinical, biochemical and anthropometric assessment in the course of research studies. Values of FLI and LAP were determined, and assessed both as predictors of the presence of hepatic steatosis (liver fat >5.5 %) and of actual liver fat content, as measured by 1H MRS. The discriminative ability of FLI and LAP was estimated using the area under the Receiver Operator Characteristic curve (AUROC). Since FLI can also be interpreted as a predictive probability of hepatic steatosis, we assessed how well calibrated it was in our cohort. Linear regression with prediction intervals was used to assess the ability of FLI and LAP to predict liver fat content.
Results. FLI and LAP discriminated between patients with and without hepatic steatosis with an AUROC of 0.79 (IQR= 0.74, 0.84) and 0.78 (IQR= 0.72, 0.83), although quantitative prediction of liver fat content was unsuccessful. Additionally, the algorithms accurately matched the observed percentages of patients with hepatic steatosis in our cohort.
Conclusions. FLI and LAP may be used clinically, and for metabolic and epidemiological research, to identify patients with hepatic steatosis, but not as surrogates for liver fat content.
|Additional Information:||This manuscript has been accepted for publication in European Journal of Endocrinology, but the version presented here has not yet been copy-edited, formatted or proofed. Consequently, Bioscientifica accepts no responsibility for any errors or omissions it may contain. The definitive version is now freely available at http://dx.doi.org/10.1530/EJE-14-0112|
|Uncontrolled Keywords:||1103 Clinical Sciences, 1114 Paediatrics And Reproductive Medicine|
|Subjects:||R Medicine > RC Internal medicine > RC1200 Sports Medicine|
|Divisions:||Sport & Exercise Sciences|
|Date Deposited:||13 Jan 2016 14:19|
|Last Modified:||13 Jan 2016 14:19|
|DOI or Identification number:||10.1530/EJE-14-0112|
Actions (login required)